A significant leap forward in the intricate science of pain management is emerging from researchers at USF Health, whose latest investigations are illuminating novel mechanisms by which opioid compounds interact with the body. This groundbreaking work fosters considerable optimism for the future development of pain-relieving medications that could offer substantial therapeutic benefits without the pervasive and often life-threatening side effects that have characterized current opioid treatments. The implications of these findings extend beyond mere pain relief, potentially opening new avenues for addressing addiction and other neurological conditions.
The cornerstone of this scientific advancement lies in two concurrently published studies, appearing in the prestigious journal Nature and its companion publication Nature Communications. The Nature paper, titled "GTP release-selective agonists prolong opioid analgesic efficacy," details specific experimental compounds that modulate mu opioid receptors. Simultaneously, a study in Nature Communications, "Characterization of the GTPĪ³S release function of a G protein-coupled receptor," further elaborates on the nuanced functional characteristics of these critical cellular components.
Dr. Laura M. Bohn, PhD, a distinguished figure in the field and senior associate dean for Basic and Translational Research at the USF Health Morsani College of Medicine, articulated the overarching mission driving this research. "Our overarching research aims to understand how opioids work so that we can ultimately provide safer options for chronic pain and develop therapies for opioid use disorders," she stated, underscoring the dual focus on both therapeutic efficacy and mitigating the societal burden of opioid addiction.
Opioid receptors, specifically the mu opioid receptor, are proteins embedded within the membranes of nerve cells, acting as crucial intermediaries in the transmission of pain signals. When activated by opioid agonists, such as morphine, these receptors initiate a cascade of intracellular events that effectively dampen pain perception. However, this same activation pathway is notoriously associated with a range of adverse effects, most critically respiratory depression, which is a primary driver of fatal opioid overdoses. Dr. Bohn and her dedicated team are meticulously dissecting the molecular choreography of receptor activation, seeking to untangle the pathways responsible for analgesia from those that precipitate harm. Their research is revealing a previously unappreciated complexity in receptor behavior, demonstrating that different drugs can elicit distinct functional outcomes upon binding.
Edward Stahl, PhD, an assistant professor of Molecular Pharmacology and Physiology at the Morsani College of Medicine and a corresponding author on the Nature study, emphasized the fundamental nature of their discoveries. "Our manuscripts describe a unique way that drugs can control receptors," Dr. Stahl explained, highlighting the novelty of their approach. He further elaborated on the profound implications for the broader scientific community: "Fundamentally, knowing more about how receptors work is the first step in understanding how to drug them and how to drug them safer. If this research is further validated, it would add to our textbook knowledge of how receptors function and, more importantly, to our ability to treat human health and disease." The research, supported by vital funding from the National Institutes of Health, represents a significant enhancement of our foundational understanding of G protein-coupled receptors (GPCRs), a vast family of cellular targets that are central to a multitude of physiological processes and are the targets of a substantial proportion of currently prescribed medications.
The traditional understanding of opioid action posits a linear progression of intracellular signaling events initiated upon receptor activation. This process, while effective in blocking pain signals, also triggers the undesirable effects of respiratory suppression and the development of tolerance, wherein higher doses are required over time to achieve the same analgesic effect. The USF Health team’s critical insight is the identification of a potential "reversal" of this signaling cascade. Certain experimental compounds, they have discovered, appear to preferentially engage with a retrograde or reverse signaling pathway, rather than the conventional forward pathway that leads to both pain relief and side effects.
Dr. Bohn elaborated on this pivotal finding: "We’ve found that the first step of the chain reaction is reversible, and that some drugs can favor a reverse reaction over the forward reaction." She further detailed the experimental evidence: "We’ve studied two new chemicals that strongly favor the reverse cycle and, when administered at non-effective doses, can enhance morphine and fentanyl-induced pain relief while not enhancing the respiratory suppression effects." This suggests a remarkable decoupling of analgesic efficacy from respiratory compromise, a holy grail in opioid pharmacology.
It is crucial to temper expectations regarding the immediate clinical translation of these specific compounds. The researchers explicitly state that these molecules are not yet considered drug candidates. At higher dosages, they can still induce respiratory depression, and comprehensive testing for toxicity and other opioid-related adverse effects has not yet been conducted. Nevertheless, their true value lies in the conceptual framework they provide for the rational design of future generations of opioid-based therapeutics. "They do provide the framework for building new drugs," Dr. Bohn affirmed, pointing to their utility as molecular blueprints.
This current work builds upon a foundation of earlier breakthroughs from Dr. Bohn’s laboratory, notably the identification of a compound designated SR-17018. Unlike conventional opioids, SR-17018 demonstrated a notable absence of respiratory suppression and tolerance. This compound, while also interacting with the mu opioid receptor, does so through a distinct binding modality. This alternative interaction preserves the receptor’s availability for the body’s own endogenous opioid peptides, which are natural pain-modulating substances. While SR-17018 also exhibits a preference for the reverse signaling pathway, the researchers hypothesize that other, yet-to-be-fully-elucidated, structural and functional features contribute to its enhanced safety profile. "For this reason," Dr. Bohn stated, "we will be using our new findings to improve upon SR-17018." This iterative approach, refining existing promising leads with new mechanistic insights, is characteristic of advanced drug discovery.
The potential impact of this research extends far beyond the realm of opioid pain management. The principle of selective receptor activation, particularly the ability to steer signaling towards a reverse or biased pathway, could have profound implications for the development of drugs targeting other GPCRs. Receptors such as the serotonin 1A receptor, a critical target in neuropsychiatric disorders like depression and psychosis, are also modulated by drugs. Dr. Bohn noted the broad applicability of their findings: "this is an important drug target in neuropsychiatric disorders, including depression and psychosis." The ability to selectively activate or inhibit specific signaling branches of these receptors could lead to more targeted and effective treatments with fewer off-target effects for a wide array of complex conditions.
These scientific advancements arrive at a critical juncture, amidst an ongoing public health crisis fueled by the misuse and addiction to opioid medications. Official data underscore the severity of this epidemic, with opioids implicated in a substantial percentage of overdose fatalities. The pervasive presence of potent synthetic opioids like fentanyl has exacerbated this crisis, leading to unprecedented mortality rates. In this context, the pursuit of safer alternatives is not merely an academic endeavor but a pressing public health imperative.
Dr. Bohn’s recent relocation to USF Health signifies a strategic infusion of expertise into the institution. An internationally recognized authority in molecular pharmacology and neurobiology, she has been instrumental in unraveling the complexities of GPCR function. Her laboratory’s prior contributions have been pivotal in demonstrating how biased agonism at opioid receptors can achieve pain relief without the debilitating consequences of respiratory suppression and tolerance. These cumulative findings not only deepen the scientific understanding of opioid biology but also represent a tangible stride towards the development of pain management strategies that are both effective and devoid of the risks that have plagued traditional opioid therapies, offering a glimmer of hope for a safer future in pain care.
About the Author
